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Abstract
Background: Hepatocellular carcinoma (HCC) with bile duct tumour thrombus (BDTT) is rare. The aim
of the present study was to determine the prognosis of HCC with BDTT after a hepatectomy.
Methods: A retrospective analysis was performed on all HCC patients with BDTT having a hepatectomy
from 1989 to 2012. The outcomes in these patients were compared with those in the control patients
matched on a 1:6 ratio.
Results: Thirty-seven HCC patients with BDTT having a hepatectomy (the BDTT group) were compared
with 222 control patients. Patients in the BDTT group had poorer liver function (43.2% had Child–Pugh B
disease). More patients in this group had a major hepatectomy (91.9% versus 27.5%, P = 0.001), portal
vein resection (10.8% versus 1.4%, P = 0.006), en-bloc resection with adjacent structures (16.2% versus
5.4%, P = 0.041), hepaticojejunostomy (75.7% versus 1.6%, P < 0.001) and complications (51.4% versus
31.1%, P = 0.016). The two groups had similar hospital mortality (2.7% versus 5.0%, P = 0.856), 5-year
overall survival (38.5% versus 34.6%, P = 0.59) and 5-year disease-free survival (21.1% versus 20.8%,
P = 0.81). Multivariate analysis showed that lymphovascular permeation, tumour size and post-operative
complication were significant predictors for worse survival whereas BDTT was not.
Discussion: Amajor hepatectomy, extrahepatic biliary resection and hepaticojejunostomy should be the
standard for HCC with BDTT, and long-term survival is possible after radical surgery.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and the ninth in women and is the second most
common cause of cancer death worldwide.1 Jaundice is a poor
prognostic sign and occurs in 5–44% of HCC patients.2 It is often
caused by tumour infiltration or liver failure owing to underlying
decompensated cirrhosis. Obstructive jaundice is a rare phenom-
enon and the first case of obstructive jaundice in HCC was
reported in 1947 by Mallory et al. where the tumour invaded the
gall bladder and caused extrinsic compression of the bile duct.3
Besides direct tumour invasion, obstructive jaundice could also be
caused by bile duct tumour thrombus (BDTT), haemobilia and
extrinsic compression of the bile duct by metastatic lymphad-
enopathy at the porta hepatis.2 Among them, BDTT in HCC is a
special clinical entity as the pathological characteristics of these
tumours and their impact on disease prognosis remain unclear.
Obstructive jaundice together with the very often
concomintant haemobilia and cholangitis caused by BDTT has
made the assessement and evaluation of hepatectomy difficult.
Treatment such as resection, transarterial chemoembolization or
systeminc treatment for HCC is usually not possible as a result of
poor liver function. The prognosis of HCC with BDTT is also not
well understood.4,5 There is controversy whether HCC with BDTT
has the same outcomes after hepatectomy as HCC without
BDTT.5–12 Besides prognosis, evidence is lacking on the preferred
method for biliary drainage, extent of hepatectomy and the need
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for extrahepatic bile duct resection and hepaticojejunostomy (HJ)
in these patients.6–8,13–20 The aim of this study was to review the
pathological characteristics of HCC with BDTT and the outcomes
of these tumours after a hepatectomy.
Patients and methods
From January 1989 to December 2012, 1459 patients underwent a
hepatectomy for HCC at the Department of Surgery, Queen
Mary Hospital, The University of Hong Kong, Hong Kong. Base-
line demographic data of patients including age, gender, liver
function, medical comorbidity and hepatitis status, as well as
clinicopathological data including tumour size, number, site,
radiological features of tumour, operative details and histology of
resected tumours, were prospectively collected and entered into a
computerized database. Thirty-seven patients with pathologically
confirmed HCC with BDTT were identified and their outcomes
were compared with those of the 222 (1:6) control patients (i.e.
HCC without BDTT) during the same study period. The
matching criteria were TNM stage (UICC 6th edition) and
lymphovascular permeation status.
Pre-operative assessment
All patients had contrast computed tomography (CT) ormagnetic
resonance imaging (MRI) to evaluate liver or biliary pathology.
Assessment of liver function was based on patients’ liver biochem-
istry, coagulation profile, Child–Pugh classification and the
indocyanine green (ICG) clearance test. Before 1997, ICG reten-
tion at 15 min (ICG R-15) of ≤14%was considered the safety limit
for a major hepatectomy. Since 1997, the safety limit has been
extended to ICG R-15 up to 20%.21,22 A major hepatectomy was
defined as resection of three or more Couinaud liver segments.23
CT volumetry of the liver was performed to evaluate the size of the
liver remnant. Portal vein embolization was done to induce hyper-
trophy of the contralateral lobe if the remnant liver volume was
≤30%.
Pre-operative biliary drainage
In patients with biochemical and radiological features of biliary
obstruction, biliary drainage was indicated and the choice
between endoscopic retrograde cholangiopancreatography
(ERCP) and percutaneous transhepatic biliary drainage (PTBD)
was based on individual surgeons’ preference. ERCP at our centre
was performed by the same team of hepatobiliary surgeons. In
general, ERCP was the drainage method of choice as it was asso-
ciated with lower procedure risks and obviated the problems of
external drainage. A proper cholangiogram was essential to dem-
onstrate the extent of BDTT, as it would guide our subsequent
resection strategy. Extraction of BDTT would be done whenever
possible, using a balloon catheter and stone basket to facilitate
bile drainage. In the case of obstructive jaundice, drainage of
the remnant liver was mandatory. For the tumour involved
lobe, drainage was performed whenever there was biliary sepsis.
An antibiotic was prescribed according to bile bacteriology.
Aggressive biliary drainage was an important step to improve
patients’ liver function and to treat cholangitis. Therefore, more
than one attempt of ERCP/PTBD might be necessary and some-
times with a combined approach (both ERPC and PTBD) as well.
A total bilirubin level ≤50 umol/l or a decrease in total bilirubin
level by >50% and the absence of sepsis were prerequisites for a
major hepatectomy.
Operative details
In general, our standard procedure was a major hepatectomy with
extrahepatic bile duct resection with HJ in HCC with BDTT.
Resection of the main portal vein and reconstruction would be
performed if the main portal vein was encased. The ultimate goal
for surgery was clearance of the tumour (both macroscopic and
microscopic) and because of potential seeding of tumour cells
along the bile duct into the common bile duct, resecting the ext-
rahepatic bile duct with HJ reconstruction has been our routine in
the past 15 years.
Our operative techniques were published in detail previously.24
Patients were given a light meal on the day before a hepatectomy.
Antibiotic and proton pump inhibitor were given at induction of
anaesthesia. Surgery was performed usually through a right
subcostal incision with midline extension, sometimes converted
to a bilateral subcostal incision if necessary. A full laparotomy was
done to rule out occult metastasis. Intra-operative ultrasonogra-
phy was performed routinely to detect an additional nodule, to
determine the tumour margin and the transection plane, and to
define the tumor’s relationship with major vasculatures. A liver
transection was performed using an ultrasonic dissector. Branches
of the bile duct and vessels were controlled with metal clips or
ligatures. The anterior approach was reserved for patients with
large tumours. The Pringle manoeuvre was not used routinely
unless liver transection was difficult as a result of venous conges-
tion. The hepatic vein was divided extrahepatically with a vascular
linear stapler (Ethicon Endo-surgery, Cincinnati, OH, USA). The
hepatic duct and common bile duct were isolated and divided, the
hepatic duct and distal common bile duct margins were sent for
frozen section to rule out tumour involvement. The extrahepatic
bile duct was delivered en bloc with a hepatectomy specimen.
Bilioenteric reconstruction was fashioned with Roux-en-Y HJ
using 6/0 PDS, the posterior layer was sutured in a continuous and
the anterior layer was sutured in an interrupted manner. No
biliary stent or splintage tube was inserted to the HJ.
Meticulous attention was paid to protect the liver remnant with
avoidance of excessive rotation or compression. Haemostasis was
secured using diathermy, argon beam coagulator and sutures.
Thorough irrigation with normal saline was performed and no
drain was deployed unless there was doubt about bile leakage.
Post-operative care
After surgery, all patients who had a major hepatectomy were
cared for in the high-dependency unit. Patients were extubated
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whenever possible as determined by the anaesthetists. Pain relief
was delivered via a patient-controlled-intravenous morphine
infusion. A broad-spectrum antibiotic was given for 3 days
and intravenous albumin was prescribed in patients with
hypoalbuminaemia. In selected patients with cirrhosis, parenteral
nutrition consisting of branched chained amino acid andmedium
chain triglyceride was started immediately after operation for 5 to
7 days. Oral feeding was introduced once gastrointestinal function
returned.
Follow-up for recurrence
Post-operative adjuvant therapy was not given except in the case
of pathologically confirmed margin involvement. All patients
were followed up by the same team of hepatobiliary surgeons
monthly in the first year and then every 3 months thereafter.
Contrast CT or MRI was arranged at 1 month after a hepatectomy
and then quarterly for the first year and every 6 months after-
wards. Recurrence was managed with multimodality treatments
including resection, ablative therapy, transarterial chemoem-
bolization or systemic therapy.
Statistical analysis
All data were prospectively collected and stored in a computerized
database. Hospital mortality was defined as death of any cause
that occurred during the same hospitalization for a hepatectomy.
Complications were reported and graded according to Clavien–
Dindo classification.25 All HCC and BDTT were confirmed
histologically. Continuous variables were expressed in the mean
(range) and compared using the t-test or the Mann–Whitney
U-test. Categorical variables were compared using Pearson’s chi-
squared test. Survival analyses were performed using the Kaplan–
Meier method and comparison between groups was made by the
log-rank test. Cox’s proportional hazard was used to identify pre-
dictors for overall survival. Statistical significance was defined as P
< 0.05. All statistical analyses were performed using the statistical
software PASW 16 (SPSS Inc., Chicago, IL, USA).
Results
During the study period, 1459 HCC patients underwent a hepa-
tectomy for HCC at our centre and 37 (2.5%) patients had patho-
logical confirmation of BDTT.Outcomes of these 37 patients were
compared with 222 control patients (i.e. those who had under-
gone hepatectomy for HCC without BDTT) at the same period in
a ratio of 1:6 using TNM (UICC 6th edition) and lymphovascular
permeation status as matching criteria. The median follow-up
time was 24.9 months.
Pre-operative details
Thirty-one out of the 37 patients with BDTT required biliary
drainage before a hepatectomy. Only six patients had a hepatec-
tomy without pre-operative biliary drainage because these
patients had normal liver function as only secondary bile duct
branches were involved by BDTT. Among those who had drain-
age, four patients had PTBD, 22 patients underwent ERCP and
five had the combined approach (both ERCP and PTBD). Nine-
teen out of the 37 patients had cholangitis with bactibilia before
the operation. The median total bilirubin levels before and after
biliary drainage in patients with BDTT were 143.1 (50–712)
umol/l and 25.1 (3–63) umol/l, respectively. The median number
of biliary drainage before hepatectomy was 1.8 (0–4) and the
median time from first biliary drainage to hepatectomy was 0.9
(0.1–6.7) months. Baseline demographic data of all patients are
listed in Table 1. The BDTT group and the control group were
similar in terms of age, gender, comorbidity and hepatitis status.
Patients with BDTT had a higher serum total bilirubin level before
hepatectomy than the control patients (25.1 versus 11 umol/l,
P < 0.001) and lower serum albumin levels (37 versus 40 g/dl,
P = 0.001). These in turn was reflected in the difference in
Child–Pugh grade among them (Child–Pugh B: 43.2% versus
3.2%, P < 0.001). Pre-operative ICG R-15 was the same among all
patients (12.9% versus 11.4%, P = 0.352).
Operative details and post-operative outcomes
Table 2 shows the operative details of all patients. Operative
details were different between the two groups. The majority (34
out of 37) of HCC patients with BDTT had a major hepatectomy.
All minor hepatectomies in the BDTT group were a left lateral
sectionectomy. Four patients in the BDTT group and three (1.4%)
patients in the control group required portal vein resection.
En-bloc resection with other organs was more common in the
BDTT group (16.2% versus 5.4%, P = 0.041). At the beginning of
our study, resection of the extrahepatic bile duct with HJ was yet
an established standard, and therefore nine patients in the BDTT
group did not have HJ. Twenty-eight patients in the BDTT group
and three (1.4%) patients in the control group had resection of
the extrahepatic bile duct and HJ (P < 0.001). As a result of a
major hepatectomy and more complex surgeries, the operating
time for patients with BDTT was significantly longer (465 versus
402 min, P = 0.003) with more blood loss (1.47 versus 0.96 litres,
P = 0.024).
Patients in the BDTT group were more likely to have compli-
cations after a hepatectomy (51.4% versus 31.3%, P = 0.016). The
majority of these complications were grade 3a (37.8% versus
16.7%, P = 0.003) and there was no difference between the two
groups in grade 3b (5.4% versus 2.3%, P = 0.584) and grade 4a
complications (2.7% versus 3.6%, P = 1.000). Hospital stay was
longer in the BDTT group (23.5 versus 11.0 days, P = <0.001) as a
result of more complex surgeries and more post-operative
complications but had not led to a higher hospital mortality
(2.7% versus 5.0%, P = 0.856).
Pathological analyses
As TNM stage (UICC 6th edition) and lymphovascular permea-
tion status were used as the matching criteria, pathological char-
acteristics were similar between the two groups (Table 3).Analyses
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Table 1 Baseline demographics of all patients
BDTT
N = 37
Control
N = 222
P-value
Age (median, range) 57 (27–86) 56 (19–79) 0.984
Gender (male : female) 29:8 179:43 0.750
HBsAg positive (n, %) 30 (81.1) 178 (80.2) 0.917
Comorbidity ≥1 (n, %) 13 (35.1) 69 (31.1) 0.624
AFP, ng/ml 50 (2–63 320) 162 (1–1 335 900) 0.710
Creatinine, umol/l 77.5 (46–123) 83 (34–370) 0.158
Albumin, g/dl 37 (22–51) 40 (26–52) 0.001
Total bilirubin, umol/l 25.1 (3–63) 11 (2–33) <0.001
INR 1.1 (0.6-1.4) 1 (0.9-1.4) 0.103
ICG R-15 (%) 12.9 (3.6–37.6) 11.4 (1.6–83.5) 0.352
Child–Pugh classification (n, %)
A 21 (56.8) 219 (96.8) <0.001
B 16 (43.2) 7 (3.2)
UICC 6th edition
I 9 (24.3) 54 (24.3) 1.000
II 6 (16.2) 36 (16.2)
III 20 (54.0) 120 (54.0)
IV 2 (5.4) 12 (5.4)
BDTT, bile duct tumour thrombus; HBsAg, hepatitis B surface antigen; ICG R-15, indocyanine green retention at 15 min.
Table 2 Comparison of operative variables
BDTT
N = 37
Control
N = 222
P-value
Major hepatectomy (n, %) 34 (91.9) 61 (27.5) 0.001
Main portal vein resection (n, %) 4 (10.8) 3 (1.4) 0.006
En bloc resection with adjacent structures (n, %) 6 (16.2) 12 (5.4) 0.041
Diaphragm 2 10
Kidney 1 0
Colon 1 0
Adrenal 2 2
Hepaticojejunostomy (n, %) 28 (75.7) 3 (1.6) <0.001
Blood loss (litres) 1.47 (0.2–15) 0.96 (0.05–20) 0.024
Operating time (min) 465 (210–1349) 402 (120–840) 0.003
Hospital stay (days) 23.5 (5–198) 11 (3–128) <0.001
Hospital mortality (n, %) 1 (2.7) 11 (5.0) 0.856
Complication rate (n, %) 19 (51.4) 69 (31.3) 0.016
Intra-abdominal collection 4 (10.8) 5 (2.3)
Intra-abdominal bleeding 2 (5.4) 4 (1.8)
Biliary fistula/ leak 2 (5.4) 6 (2.7)
Pneumonia/pleural effusion 5 (13.5) 9 (4.1)
Clavien–Dindo classification of complications (n, %)
IIIA 14 (37.8) 37 (16.7) 0.003
IIIB 2 (5.4) 5 (2.3) 0.584
IVA 1 (2.7) 8 (3.6) 1
IVB 0 0 –
BDTT, bile duct tumour thrombus.
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of resected specimens showed that 22 out of the 37 patients in
the BDTT group had solitary HCC with a median size of 6 cm.
A significant proportion of HCC with BDTT had lymphovascular
permeation (25/37) and was of a poorly differentiated grade
(11/37). Almost all tumours with BDTT (35/37) were not
encapsulated.
Survival and recurrence data
Overall survival (OS) and disease-free survival (DFS) were com-
parable between the two groups. The median OS and DFS for
HCC patients with BDTT were 44 and 9.7 months, respectively,
similar to those of the control patients (31.7 and 8.7 months
respectively). The 1-, 3- and 5-year OS and DFS rates are shown in
Figs 1 and 2 respectively.
The recurrence pattern was similar between the groups. Four-
teen out of the 37 patients in the BDTT group and 63 out of the
222 (28.4%) patients in the control group had no recurrence at
last follow-up. Among those with recurrence, an intra-hepatic
recurrence was the commonest [12/23 in the BDTT group and
73/159 (45.9%) in the control group]. Isolated extrahepatic
metastasis occurred in 17.4% and 18.2% (29/159) of the patients
in the BDTT and control groups, respectively. Concomitant
intrahepatic and extrahepatic disease occurred in the remaining
one-third of patients [7/23 in the BDTT group and 57/159
(35.8%) in the control group]. The lung is the commonest site
of extrahepatic recurrence [13% versus 23.3% (BDTT versus
control), P = 0.268]. Recurrence in the biliary tract was rare and
occurred in only one patient in the BDTT group. This patient was
one of the nine patients in whom extrahepatic bile duct resection
and HJ reconstruction was not done in the primary operation. He
presented with obstructive jaundice 11 months after a hepatec-
tomy and an isolated recurrence at the common bile duct was
found. The Whipple procedure was performed as salvage and the
patient remains disease-free since then. The risk of bile duct recur-
rence in patients with or without HJ did not reach statistical
significance (11.1% versus 0%, P = 0.090).
An exploratory multivariate analysis with the use of a Cox
proportional hazard model identified the prognostic factors for
OS and DFS (Table 4). Poor prognostic factors for OS were a
tumour with lymphovascular permeation [hazard ratio (HR)
3.10, 95% confidence interval (CI) 2.12–4.53], tumour size (HR
1.09, 95% CI 1.05–1.12) and occurrence of post-operative com-
plications (HR 1.41, 95% CI 1.03–1.92). Tumour size (HR 1.06,
95% CI 1.02–1.11), lymphovascular permeation (HR 3.36, 95%
CI 2.37–4.76) and blood loss (HR 1.12, 95% CI 1.02–1.22)
predicted DFS. The presence of BDTT was not a significant prog-
nostic predictor for OS or DFS.
Discussion
BDTT is uncommon in HCC patients. The reported incidence
ranges from 0.53% to 13%2,12,26 and the presence of BDTT usually
implies a poor prognosis. The perceived inferior prognosis is a
result of inadequate understanding of pathological characteristics
of these tumours, ineffective biliary drainage to alleviate jaundice,
a low rate of hepatectomy owing to poor liver function and failure
to recognize the importance of a major hepatectomy with extra-
hepatic bile duct resection. The present study has demonstrated
that HCC patients with and without BDTT had comparable OS
and comparable DFS. BDTT alone has no impact on survival or
recurrence after a hepatectomy if appropriate treatment is given.
Table 3 Pathological analysis of all resected HCCs
BDTT
N = 37
Control
N = 222
P-value
Size of tumour (cm, median
and range)
6 (1–25) 7 (1–23) 0.088
Solitary tumour (n, %) 22 (59.5) 123 (55.4) 0.734
Poorly differentiated tumour (n, %) 11 (29.7) 46 (20.7) 0.592
Tumour encapsulation (n, %) 2 (5.4) 58 (26.1) 0.002
Lymphovascular permeation (n, %) 25 (67.6) 150 (67.6) 1.000
Resection margin involved (n, %) 2 (5.4) 15 (6.8) 1.000
BDTT, bile duct tumor thrombus.
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Figure 1 Comparison of overall survival
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It is crucial to understand the tumour behaviour and pathology
of HCC with BDTT. In the present series, these tumours were
mostly not encapsulated (94.6%) and 67.6% had lymphovascular
permeation. For HCCwithout BDTT, the average lymphovascular
permeation rate was 27.9% and 38% in solitary and multiple
HCC, respectively,27 and it was 27% as recorded in the western
literature.28 The incidence of lymphovascular permeation of
67.6% was more than double the average rate in HCC without
BDTT. Lymphovascular permeation is undoubtedly a well-
documented risk factor for worse disease prognosis.24 A lack of
tumour encapsulation is another risk factor. It was shown in a
recent study that complete tumour encapsulation predicted better
OS, a better response to downstaging therapy and eventual liver
transplantation.29 Last but not least,macrovascular invasion to the
main portal vein or its branches was seen in 9 of the 37 patients.
These pathological characteristics also provide clues to the under-
lying pathogenesis of BDTT.While the exact mechanism of BDTT
in HCC is unknown and it has been postulated that it is caused by
direct tumour invasion to the biliary system and shedding of
tumour cells along the bile duct epithelium and haemobilia, even-
tually leading to obstructive jaundice.2,9,12–14 It is not surprising,
therefore, to realize that these tumours actually have a great pro-
pensity to invade blood vessels (both micro- and macroscopic)
and are mostly not encapsulated.
The patients in the present study indeed had high-risk HCC,
and the aggressive histological features can explain the contro-
versy in the published series: whether HCC with BDTT implies
inferior survival after a hepatectomy. There are a few published
series comparing surgical outcomes of HCC with and without
BDTT, and some reported survival rates9,10 similar to that in the
present study while more reported worse prognosis in patients
with BDTT.5,8,11,12 It is believed that such a difference stems from
the inability to recognize the associated aggressive features of
HCC with BDTT and comparison is unjust unless tumour stage
and microvascular permeation are matched. It was the drawback
in other series where the tumour stage was far more advanced
and macrovascular invasion was more common in HCC with
BDTT.5,8,11,12 If one ignored these features and compared HCC
with BDTT to ‘average’ HCC, the prognosis would be undoubt-
edly worse with the former. After adjusting these factors, the
present study demonstrated that BDTT alone was not a significant
predictor for OS and DFS. Instead, conventional prognostic
factors including tumour size, lymphovascular permeation and
post-operative complication predicted a worse OS.
Another controversy is whether a major hepatectomy and ext-
rahepatic bile duct resection are necessary. It is conventional to
classify BDTT according to Ueda classification30 as it may predict
the occurrence of obstructive jaundice and even the extent of a
hepatectomy.We propose that a major hepatectomy and extrahe-
patic bile duct resection are necessary in the management of all
patients with BDTT irrespective of Ueda classification. In our
series, 6 patients did not require preoperative biliary drainage as
they had Ueda 1 or 2 BDTT. All patients except those with Ueda 1
(3 patients) showed radiological evidence of bile duct dilatation
and intraductal mass. The presence of a dilated biliary tree and
intraductal mass on pre-operative CT raises the suspicion of HCC
complicated by BDTT, but clinically it is almost impossible to
locate the exact site and extent of HCC invasion to the bile duct on
CT or even with direct cholangiogram. Tumour thrombus and
haemobilia are usually necrotic and friable and can be easily
removed by a balloon catheter,31 the apparent clearance of biliary
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Figure 2 Comparison of disease-free survival
Table 4 Prognostic factors for overall survival
Hazard
ratio
95%
confidence
interval
P-value
Tumour size (cm) 1.09 1.05–1.12 <0.001
Lymphovascular permeation 3.10 2.12–4.53 <0.001
Post-operative complication 1.41 1.03–1.92 0.032
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tree can be misleading as microscopic invasion may have occurred
already. Therefore a non-anatomical resection and extraction of
BDTT with choledochotomy is inadequate for oncological clear-
ance and we advocate an aggressive surgical approach irrespective
of Ueda type to achieve radical resection in both the liver paren-
chyma and bile duct. With a major hepatectomy, resection of the
extrahepatic bile duct and HJ, a 5-year OS of 38.5% was achieved
in our series and bile duct recurrence could be minimized. In the
present cohort, only one out of the 37 patients had bile duct
recurrence and this patient was one in the nine patients who did
not have resection of extrahepatic bile duct or HJ. Bile duct recur-
rence did not occur in those who had HJ. This was in great con-
trast to a previous report that major hepatectomy and HJ were not
a routine and an early recurrence rate (<1 year after hepatectomy)
of 70.3% and bile duct recurrence rate of 22.2% were observed.17
The present study has demonstrated that even with an aggressive
surgical approach, there was no difference in hospital mortality
(2.7% versus 5%, P = 0.856) but only a higher morbidity (51.4%
versus 31.3%, P = 0.016). Most of these complications were of
grade 3a (37.8% versus 16.7%, P = 0.003) and there was no
difference in more serious complications such as those of grade
3b (5.4% versus 2.3%, P = 0.584) or grade 4 (2.7 versus 3.6%,
P = 1.000).
Aggressive pre-operative biliary drainage is essential. Obstruc-
tive jaundice and superimposed cholangitis jeopardize patients’
eligibility for safe hepatectomy. In the series, 51.4% of the patients
had cholangitis and the peak total bilirubin level before biliary
drainage was 143.1 umol/l. Hepatectomy, whatever the extent
might be, would be impossible with such liver function. It took an
average of 1.8 (0–4) biliary drainage procedures to lower the total
bilirubin level by >50% and to control sepsis. The clinical success
rate of biliary drainage (endoscopic or percutaneous) ranges from
48.4% to 100% in the literature.18,20,31 ERCP is more commonly
done at our centre as the risk associated with ERCP is lower and
there is no complication like catheter-related discomfort, fluid
and electrolytes loss, etc. In contrast, we consider endoscopic and
percutaneous drainage complementary. Should BDTT involve the
secondary or even more proximal part of the biliary tree, segmen-
tal segregation is the norm and drainage will be easier through
PTBD. Drainage of the remnant liver is mandatory and that of
obstructed segments is not necessary unless there is cholangitis.
Pre-operative assessment of liver function for hepatectomy should
be the same as that done for HCC without BDTT, but ICG R-15
would be erroneously high at time of obstructive jaundice. It is
often necessary to postpone a ICG test until jaundice is relieved.
Aggressive biliary drainage with ERCP/PTBD, treatment for sepsis
and nutritional support are important measures to facilitate a
hepatectomy.
HCC with BDTT is a distinct and uncommon clinical entity.
Hepatectomy remains the only curative treatment option. As a
result of the aggressive nature of these tumours (poor differentia-
tion, lack of encapsulation,macro- and microvascular invasion), a
major hepatectomy and resection of the extrahepatic bile duct
with HJ should be the standard of care to minimize recurrence. In
the study, patients with and without BDTT had comparable OS
and comparable DFS, indicating that the presence of BDTT alone
may not lead to inferior survival outcomes. Special consideration
is required to relieve jaundice, to treat sepsis and to support nutri-
tion in these patients.
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